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B-type natriuretic peptide (BNP) has been recognized as a very 
useful marker for the detection of acute and chronic left ventricular 
dysfunction, both systolic and diastolic, that can be present in the 
context of sudden and prolonged myocardial ischemia.1,2 These 
are the first steps in the ischemic cascade, leading to cell necrosis. 
For that reason, natriuretic peptides are usually elevated in the 
context of acute coronary syndromes.2 
Myocardial ischemia, even in the absence of left ventricular 
dysfunction, augments cardiac BNP gene expression, increasing 
plasma NT-proBNP concentrations.3,4 BNP kinetics usually peaks 
at 16 hours of symptom’s onset in ST-elevation myocardial 
infarction and a second peak is usually observed by the fifth 
day.5 We can speculate that the first peak might be associated 
with ischemia and the second peak to left ventricular dysfunction 
associated with cell necrosis and early remodelling. 
N-terminal-pro-BNP (NT-proBNP) is the amino-terminal 
product after cleavage of the precursor peptide of BNP. It has 
a longer half-life, allowing greater accumulation and sensitivity 
in detecting subtle structural and functional changes.5,6 NT-
proBNP has been extensively studied in the last two decades, 
particularly in the 00’s, and results consistently showed that 
early measurements provide important and independent 
information for risk stratification across the entire spectrum of 
acute coronary syndromes.7-10 Prognostic accuracy of early NT-
proBNP measurements is even better when compared to early 
cardiac troponin measurements, reflecting the ischemic insult 
rather than cell necrosis.9
GRACE risk score is currently the most widely recommended 
risk stratification score in the context of acute coronary 
syndromes.11,12 It incorporates clinical, electrocardiogram and 
biochemical markers and it is highly predictive for short- and 
medium-term mortality. For in-hospital mortality, values of Area 
Under Curve > 0.85 are usually obtained.7 However, previous 
studies did not show any additional benefit with the inclusion of 
natriuretic peptides in this risk stratification tool.7
The article by Souza et al.13 studied the independent predictive 
value of NT-pro-BNP compared to Killip-Kimbal class in patients 
with the whole spectrum of acute coronary syndromes and the 
potential incremental value when included in GRACE risk score in 
substitution of Killip class.13 They studied 352 patients with a mean 
age of 63 years, 60% males, 26% with ST-elevation myocardial 
infarction and in-hospital cardiovascular mortality was 4.8%. 
NT-pro-BNP was measured on admission, at a median of 15.5 
hours after symptoms onset and 29% showed increased levels. 
NT-pro-BNP showed a moderate predictive accuracy with an 
AUC of 0.78, better than Killip class. However, it was not superior 
compared to the traditional GRACE risk score (AUC 0.82) or when 
included in GRACE score (AUC 0.83). There was also no benefit 
in terms of reclassification analysis. 
The results presented are in line with previous studies, 
confirming, in a contemporaneous cohort of patients, the 
independent prognostic value of admission NT-proBNP in acute 
coronary syndromes and AUC results were also similar. The main 
originality of the present paper is the use of this biomarker not as an 
add-on but in substitution for Killip class, one of the clinical markers 
of GRACE risk score, justified by the collinearity expected between 
Killip class and NT-proBNP. However, even with this approach, 
NT-proBNP didn’t improve the prognostic accuracy of the GRACE 
risk score. I believe that the main explanation is that GRACE risk 
score is such a potent score, with an AUC usually reported as > 
0.85, including already very important prognostic variables, that 
is very difficult to improve even further this prognostic accuracy. 
Several other markers were tested by other authors and similar 
results of no significant improvements were obtained. Could the 
results be different in long-term follow-up? This is an important 
question that can be answered in subsequent studies.
There are also some additional limitations to the present study. 
Inclusion was performed for six years, but only 352 patients 
were included. Albeit the sample is adequate according to the 
sample size study presented, it suggests that the inclusion was not 
consecutive, and several patients were not considered. This is a 
potential source of bias. Another important fact is that no data 
is presented about important baseline characteristics. For that 
reason, we cannot assess if the sample really represents the usual 
patient’s characteristics in acute coronary syndromes cohorts. We 
also do not know what were the adjustments made in multivariate 
analysis. That is if all variables with a possible impact in prognosis 
and in NT-proBNP levels were considered in the multivariate 
adjustment. The “heart failure” definition used by the authors is 
also not clearly explained.
In conclusion, the present study shows that in a 
contemporaneous cohort of patients with the whole spectrum 
of acute coronary syndromes, although NT-proBNP has 
an independent moderate prognostic value for in-hospital 
cardiovascular mortality, it does not improve the risk stratification 
prognostic accuracy of the GRACE risk score. But do we need 
to improve it and add substantial complexity to its use? I do not 
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